ReviewCurrent rheumatology reports2015
Biomarkers for childhood-onset systemic lupus erythematosus.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Immunocyte phenotypes and childhood disease susceptibility: insights from bidirectional Mendelian randomization and implications for immunomodulatory therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Does the esv3587290 Copy Number Variation in theChildren (Basel, Switzerland) · 2024Article
- Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis.Rheumatology (Oxford, England) · 2023Article
- Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus.International journal of molecular sciences · 2021Review
- Article
- Utility of serum ferritin and soluble interleukin-2 receptor as markers of disease activity in childhood systemic lupus erythematosus.International journal of pediatrics & adolescent medicine · 2020Article
- Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus.Journal of cellular and molecular medicine · 2019Article
- Missed opportunities for timely diagnosis of pediatric lupus in South Africa: a qualitative study.Pediatric rheumatology online journal · 2017Article
- Enhancing translational research in paediatric rheumatology through standardization.Nature reviews. Rheumatology · 2016Review
- Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.BMC genomics · 2016Article
- What is damaging the kidney in lupus nephritis?Nature reviews. Rheumatology · 2016Review
- Techniques and Approaches to Genetic Analyses in Nephrological Disorders.Journal of pediatric genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Childhood-onset systemic lupus erythematosus (cSLE) is a systemic autoimmune disease characterized by the presence of autoantibodies. cSLE often affects multiple organs in the body and is known to have a poorer prognosis than adult-onset disease (Azevedo et al. 2014). Current laboratory tests are clearly insufficient for identifying and monitoring the disease. Recent studies have yielded novel biomarkers for cSLE which can be used for monitoring disease activity and response to treatment. The most encouraging biomarkers will be discussed herein and include cell-bound complement activation products, some genomic profiles, and urinary proteins such as neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and others. Previous studies suggested that a combination of the novel biomarkers might help to enhance sensitivity and specificity for early diagnosis, disease monitoring, and prediction of cSLE flares.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.